(0.34%) 5 117.09 points
(0.33%) 38 365 points
(0.38%) 15 989 points
(-0.97%) $83.04
(5.25%) $2.02
(0.34%) $2 355.20
(0.52%) $27.68
(4.14%) $960.25
(-0.26%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.25%
@ $168.85
発行日: 20 3月 2024 @ 22:35
リターン: -6.86%
前回のシグナル: 3月 19 - 04:52
前回のシグナル:
リターン: -0.14 %
Live Chart Being Loaded With Signals
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)...
Stats | |
---|---|
本日の出来高 | 77 125.00 |
平均出来高 | 238 208 |
時価総額 | 17.08B |
EPS | $0 ( 2024-02-26 ) |
次の収益日 | ( $-2.63 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -18.61 |
ATR14 | $0.246 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | Oyler John | Sell | 542 | American Depositary Shares |
2024-04-09 | Oyler John | Sell | 2 734 | American Depositary Shares |
2024-04-09 | Oyler John | Sell | 7 924 | American Depositary Shares |
2024-04-10 | Oyler John | Sell | 11 514 | American Depositary Shares |
2024-04-10 | Oyler John | Sell | 12 501 | American Depositary Shares |
INSIDER POWER |
---|
-13.06 |
Last 99 transactions |
Buy: 5 032 881 | Sell: 5 995 876 |
ボリューム 相関
BeiGene Ltd. 相関
10 最も負の相関 | |
---|---|
MARA | -0.884 |
SVFD | -0.872 |
WTER | -0.869 |
MTEK | -0.862 |
HOOK | -0.861 |
GSM | -0.861 |
RMRM | -0.858 |
NEXI | -0.856 |
MPAA | -0.854 |
SLDP | -0.853 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
BeiGene Ltd. 相関 - 通貨/商品
BeiGene Ltd. 財務諸表
Annual | 2023 |
収益: | $2.46B |
総利益: | $1.99B (81.13 %) |
EPS: | $-8.45 |
FY | 2023 |
収益: | $2.46B |
総利益: | $1.99B (81.13 %) |
EPS: | $-8.45 |
FY | 2022 |
収益: | $1.42B |
総利益: | $-511.06M (-36.09 %) |
EPS: | $-19.43 |
FY | 2021 |
収益: | $1.18B |
総利益: | $-447.86M (-38.07 %) |
EPS: | $-16.93 |
Financial Reports:
No articles found.
BeiGene Ltd.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。